Q2 2014 13F Holders as of 6/30/2014
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
9.99M
-
Shares change
-
-196K
-
Total reported value, excl. options
-
$463M
-
Value change
-
-$6.56M
-
Put/Call ratio
-
1.03
-
Number of buys
-
87
-
Number of sells
-
-64
-
Price
-
$46.33
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q2 2014
181 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2014.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.99M shares
of 14.4M outstanding shares and own 69.25% of the company stock.
Largest 10 shareholders include DIMENSIONAL FUND ADVISORS LP (951K shares), BlackRock Fund Advisors (692K shares), VANGUARD GROUP INC (548K shares), BlackRock Institutional Trust Company, N.A. (475K shares), WELLINGTON MANAGEMENT CO LLP (389K shares), Allianz Asset Management AG (383K shares), RENAISSANCE TECHNOLOGIES LLC (367K shares), BOGLE INVESTMENT MANAGEMENT L P /DE/ (284K shares), State Street Corp (280K shares), and THOMPSON SIEGEL & WALMSLEY LLC (264K shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.